Oncodesign Société Anonyme, a biotechnology company, conducts research and development work on new therapeutic and diagnostic tools along with pharmaceutical firms, biotech companies, public research institutions, and investment groups. More Details
Imperfect balance sheet with concerning outlook.
Share Price & News
How has Oncodesign Société Anonyme's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALONC has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ALONC exceeded the French Biotechs industry which returned 29.8% over the past year.
Return vs Market: ALONC exceeded the French Market which returned -6.2% over the past year.
Price Volatility Vs. Market
How volatile is Oncodesign Société Anonyme's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWe're Not So Sure You Should Rely on Oncodesign Société Anonyme's (EPA:ALONC) Statutory Earnings
2 months ago | Simply Wall StWhat Type Of Returns Would Oncodesign Société Anonyme's(EPA:ALONC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
3 months ago | Simply Wall StHas Oncodesign Société Anonyme's (EPA:ALONC) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Is Oncodesign Société Anonyme undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ALONC (€10.15) is trading above our estimate of fair value (€8.47)
Significantly Below Fair Value: ALONC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ALONC is poor value based on its PE Ratio (42.3x) compared to the XE Biotechs industry average (35.5x).
PE vs Market: ALONC is poor value based on its PE Ratio (42.3x) compared to the French market (18.3x).
Price to Earnings Growth Ratio
PEG Ratio: ALONC's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: ALONC is overvalued based on its PB Ratio (7.9x) compared to the FR Biotechs industry average (3.2x).
How is Oncodesign Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALONC's earnings are forecast to decline over the next 3 years (-0.9% per year).
Earnings vs Market: ALONC's earnings are forecast to decline over the next 3 years (-0.9% per year).
High Growth Earnings: ALONC's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ALONC's revenue (16.6% per year) is forecast to grow faster than the French market (6.7% per year).
High Growth Revenue: ALONC's revenue (16.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALONC's Return on Equity is forecast to be high in 3 years time
How has Oncodesign Société Anonyme performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALONC has a large one-off gain of €251.7K impacting its June 30 2020 financial results.
Growing Profit Margin: ALONC's current net profit margins (2.8%) are lower than last year (3%).
Past Earnings Growth Analysis
Earnings Trend: ALONC has become profitable over the past 5 years, growing earnings by -1.1% per year.
Accelerating Growth: ALONC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ALONC had negative earnings growth (-7.2%) over the past year, making it difficult to compare to the Biotechs industry average (3.1%).
Return on Equity
High ROE: ALONC's Return on Equity (10.7%) is considered low.
How is Oncodesign Société Anonyme's financial position?
Financial Position Analysis
Short Term Liabilities: ALONC's short term assets (€23.7M) exceed its short term liabilities (€16.3M).
Long Term Liabilities: ALONC's short term assets (€23.7M) exceed its long term liabilities (€14.6M).
Debt to Equity History and Analysis
Debt Level: ALONC's debt to equity ratio (52%) is considered high.
Reducing Debt: ALONC's debt to equity ratio has increased from 1.2% to 52% over the past 5 years.
Debt Coverage: ALONC's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if ALONC's interest payments on its debt are well covered by EBIT.
What is Oncodesign Société Anonyme current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALONC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALONC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALONC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALONC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALONC's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Philippe Genne, Ph.D., Founded Oncodesign Société Anonyme, serves as its Chairman of the Board and has been its Chief Executive Officer since May 18, 2010.
|Chief Financial & Administrative Officer||2.5yrs||no data||no data|
|Chief Scientific & Operating Officer||no data||no data||no data|
|Deputy Managing Director||no data||€24.34k||no data|
|Member of Executive Board||12.75yrs||no data||no data|
|Member of Executive Board||12.75yrs||no data||no data|
|Chief Information Officer & Head of Artificial Intelligence Business Unit||0.083yr||no data||no data|
|Chief Corporate Business Development Officer||0.083yr||no data||no data|
|Head of Human Resources||no data||no data||no data|
|GM, Senior EVP & Head of Oncodesign Service Business Unit||no data||no data||no data|
Experienced Management: ALONC's management team is seasoned and experienced (6.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Oncodesign Société Anonyme's company bio, employee growth, exchange listings and data sources
- Name: Oncodesign Société Anonyme
- Ticker: ALONC
- Exchange: ENXTPA
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €69.406m
- Shares outstanding: 6.84m
- Website: https://www.oncodesign.com
Number of Employees
- Oncodesign Société Anonyme
- 20 rue Jean Mazen
- B.P. 27627
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALONC||ENXTPA (Euronext Paris)||Yes||Ordinary Shares||FR||EUR||Apr 2014|
Oncodesign Société Anonyme, a biotechnology company, conducts research and development work on new therapeutic and diagnostic tools along with pharmaceutical firms, biotech companies, public research insti ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/19 20:54|
|End of Day Share Price||2020/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.